Effects of short-chain fatty acids on gut hormone release in healthy volunteers
The Impact of Short-Chain Fatty Acids on the Gut Hormone Release After Delivery in the Small Intestine and Colon
This study tests how short-chain fatty acids affect hormone release in healthy people when given in different parts of the gut to see if it changes appetite and metabolism.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 27 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | KU Leuven Academic / other |
| Locations | 1 site (Leuven) |
| Trial ID | NCT06686888 on ClinicalTrials.gov |
What this trial studies
This crossover study investigates how short-chain fatty acids (SCFA) influence gut hormone release after being administered in either the small intestine or colon of healthy participants. Participants will ingest SCFA capsules on designated test days, and blood samples will be collected at regular intervals to measure hormone levels. The study aims to determine if the site of SCFA administration affects the release of these hormones, which play a role in appetite and metabolism.
Who should consider this trial
Good fit: Ideal candidates are healthy males and females aged 18-50 with a normal BMI.
Not a fit: Patients with chronic gastrointestinal disorders or those on specific restrictive diets may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of gut hormone regulation and its implications for appetite control and metabolic health.
How similar studies have performed: While the specific approach of this study may be novel, previous research has indicated that SCFAs can influence gut hormone release, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * male and female * healthy * normal BMI (18.5-25 kg/m\^2) * age within 18-50 years Exclusion Criteria: * Chronic gastrointestinal disorders such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, chronic constipation (less than 3 stools a week) and chronic frequent diarrhoea (more than 3 stools a day) * Previous abdominal surgery, except from appendectomy * Being on a weight loss, gluten-free, lactose-free, or vegan diet * The donation of blood during the last 3 months or suffering from low blood haemoglobin levels * The use of antibiotics or other medication that affects the gastrointestinal tract 3 months preceding the study and/or during the study * The use of prebiotics or probiotics 2 weeks preceding the study and/or during the study * Pregnancy, lactation or wish to become pregnant during the study period * Previous or current substance/alcohol dependence or abuse (\> 2 units per day/14 units per week)
Where this trial is running
Leuven
- KU Leuven — Leuven, Belgium (Recruiting)
Study contacts
- Study coordinator: Riet Rosseel, Msc
- Email: riet.rosseel@kuleuven.be
- Phone: +3216373428
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.